Welcome to The Pharmacogenomics Journal
The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications. Publishing six times a year, the journal aims to provide the highest caliber of coverage concerning the effects of genetic variability on drug toxicity and efficacy, the characterization of polymorphisms relevant to drug action, and the identification of novel genomic targets for drug development.
Ranked in the top 10% of Pharmacology & Pharmacy titles*, with an impact factor that continues to rise, and a commitment to speedy online publication, Editor-in-Chief, Julio Licinio, invites you to join our mission of delivering compelling research to the scientific community by submitting your original research to The Pharmacogenomics Journal.
Volume 16, No 6
November 2016
ISSN: 1470-269X
EISSN: 1473-1150
2015 Impact Factor 4.229*
37/254 Pharmacology & Pharmacy
37/167 Genetics & Heredity
Editor:
Julio Licinio, MD
*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)
FEATURED ARTICLES
Review
Mechanisms of the placebo effect FREEReview
Effect of rosuvastatin on inflammatory and fibrinolytic biomarkers FREEOriginal Article
Genetic variation in optimizing docetaxel therapy FREEOriginal Article
Doxorubicin pathway polymorphisms and cardiotoxicity FREENEWS
The authors of a recent paper present RH panels as a cost-effective and efficient tool to identify mammalian drug targets at single-gene resolution. Using a human RH panel, the authors identified an important gene for the action of antitubulin drugs that had been overlooked by other strategies.
The results of a recent study published in The Pharmacogenomics Journal provide insight into both unique and shared clinical effects of leukotriene modifiers (LTMs) in treatment of asthma, and represent a potential mechanism for the responsiveness to leukotriene antagonists in asthma patients.
Visit Nature Publishing Group's open access funding page for information about research funders and institutions that provide funding for open access. NPG also offers an APC support service to make it easier for NPG authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.
TOP TEN MOST VIEWED PAPERS
The Top Ten charts the articles that have been downloaded most often over the previous 30 days, in HTML and PDF format, from the The Pharmacogenomics Journal website. The chart does not rank the quality, scientific significance or citation impact of the content. However, it may bring articles to your attention that you might not have otherwise noticed. We hope you enjoy them.
January 2017
-
Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders
J T McCracken, K K Badashova, D J Posey, M G Aman, L Scahill, E Tierney, L E Arnold, B Vitiello, F Whelan, S Z Chuang, M Davies, B Shah, C J McDougle & E L Nurmi
doi:10.1038/tpj.2013.23
-
Research and Reviews
Latest research highlights and reviews from the Springer Nature family of journals
-
Genetic risk and longitudinal disease activity in systemic lupus erythematosus using targeted maximum likelihood estimation
- this content is FREE
Source: Gene -
Materials and technologies for soft implantable neuroprostheses
Source: Nature Reviews Materials -
A high-throughput-compatible assay to measure the degradation of endogenous Huntingtin proteins
- this content is FREE
Source: Acta Pharmacologica Sinica
-
Genetic risk and longitudinal disease activity in systemic lupus erythematosus using targeted maximum likelihood estimation